Thursday 11.21.2024 1:15 PM |
Welcome Guest Main | Registration | Login | RSS |
|
My site
Main » 2020 » June » 02
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases
CAMBRIDGE, Mass. & OSAKA, Japan-Thursday 28 May 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.
“We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with b
...
Read more »
Views:
132
|
Added by:
africa-live
|
Date:
06.02.2020
|
|
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases
CAMBRIDGE, Mass. & OSAKA, Japan-Thursday 28 May 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.
“We’re extremely proud of the positive results ALUNBRIG has shown for newly diagnosed ALK+ NSCLC patients, particularly those with b
...
Read more »
Views:
194
|
Added by:
africa-live
|
Date:
06.02.2020
|
|
MINNEAPOLIS-Thursday 28 May 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Smiths Medical announced today it has joined several of the world’s other ventilator manufacturers in the Ventilator Training Alliance (VTA) to support frontline medical providers access to a centralized repository of ventilator training. The content can be found in a mobile app managed by Allego.
“Smiths Medical is proud to be a part of the VTA by providing training for our ventilators through the Allego app,” said Jeffrey Hohn, Vice President, Global Product and Commercial Excellence, Strategy and M&A at Smiths Medical. “Improving healthcare around the world is the foundation of our mission. During this critical time, we understand healthcare professionals need ventilator information quickly and the app enables the right care delivered to their patients, quickly.”
The VTA app connects respiratory therapists, nurses and other medical professionals with v
...
Read more »
Views:
116
|
Added by:
africa-live
|
Date:
06.02.2020
|
|
LONDON -Monday 1 June 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Schlumberger Limited (“Schlumberger”) today announced that Schlumberger Oilfield UK Plc, an indirect wholly-owned subsidiary of Schlumberger (“SLB UK”), will redeem the entire outstanding principal amount of its 4.200% Senior Notes due 2021 (CUSIP Nos. 80685QAA4/G7861RAA4; ISIN Nos. US80685QAA40/USG7861RAA44; and Common Codes 56301097/56301046) (the “Notes”). The redemption date for the Notes is June 29, 2020 (the “Redemption Date”). The Notes are currently listed on the Official List of the Luxembourg Stock Exchange and admitted to trading on the Euro MTF market.
The aggregate principal amount of the Notes outstanding is $600,000,000. The Notes will be redeemed on the Redemption Date at a redemption price for the Notes equal to (a) 100% of the aggregate principal amount being redeemed, plus (b) accrued and unpaid on the Notes from the last interest payment dat
...
Read more »
Views:
133
|
Added by:
africa-live
|
Date:
06.02.2020
|
|
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
Validation of Type II Variation will allow Takeda to commence launches in Europe later this year
The pre-filled syringe presentation is designed to enhance the treatment administration experience for HAE patients receiving TAKHZYRO
Views:
132
|
Added by:
africa-live
|
Date:
06.02.2020
|
|
not emptyVANCOUVER, British Columbia-Thursday 28 May 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Today, Delta-Q Technologies (Delta-Q) introduces its latest sealed charger with the RQ350 for electric vehicles and industrial machines.
Having found significant market success with the IC Series chargers rated from 650 to 1200 watts, Delta-Q has set its sights on lower power applications with its new 350-watt charger. This new build was designed and tested to meet automotive levels of product reliability, improving machine runtimes.
“The RQ350 is a response to our customers’ needs in multiple application segments,” says Lloyd Gomm, VP of Business Development. “Our customers have asked us to bring our high reliability charger design into both lower and higher capacity battery charging applications. The RQ350 solidly answers the former need with a well thought out design offered at an OEM affordable price.”
Designed for demanding app
...
Read more »
Views:
151
|
Added by:
africa-live
|
Date:
06.02.2020
|
| |
|